Jia-Shiuan Ju - Search Results

Year	Number of Results
2021	4
2022	5
2023	4
2024	2

1

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.

Hsu PC, Lee SH, Chiu LC, Lee CS, Wu CE, Kuo SC, Ju JS, Huang AC, Li SH, Ko HW, Yang CT, Wang CC. Hsu PC, et al. Among authors: ju js. Target Oncol. 2023 Mar;18(2):195-207. doi: 10.1007/s11523-023-00946-w. Epub 2023 Feb 20. Target Oncol. 2023. PMID: 36805452 Free PMC article.

2

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC.

Ju JS, Huang AC, Tung PH, Huang CH, Chiu TH, Wang CC, Ko HW, Chung FT, Hsu PC, Fang YF, Guo YK, Kuo CS, Yang CT. Ju JS, et al. Sci Rep. 2023 Nov 21;13(1):20323. doi: 10.1038/s41598-023-45815-8. Sci Rep. 2023. PMID: 37989860 Free PMC article.

3

Predicting mortality in non-cystic fibrosis bronchiectasis patients using distance-saturation product.

Lin CY, Hsieh MH, Fang YF, Peng CW, Ju JS, Lo YL, Lin SM, Lin HC. Lin CY, et al. Among authors: ju js. Ann Med. 2021 Dec;53(1):2034-2040. doi: 10.1080/07853890.2021.1999490. Ann Med. 2021. PMID: 34761709 Free PMC article.

4

Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.

Huang CH, Ju JS, Chiu TH, Huang AC, Tung PH, Wang CC, Liu CY, Chung FT, Fang YF, Guo YK, Kuo CS, Yang CT. Huang CH, et al. Among authors: ju js. Int J Cancer. 2022 Feb 15;150(4):626-635. doi: 10.1002/ijc.33821. Epub 2021 Oct 26. Int J Cancer. 2022. PMID: 34558665 Free article.

5

The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis.

Chiu TH, Tung PH, Huang CH, Ju JS, Huang AC, Wang CC, Ko HW, Hsu PC, Fang YF, Guo YK, Kuo CS, Yang CT. Chiu TH, et al. Among authors: ju js. Sci Rep. 2022 Mar 15;12(1):4398. doi: 10.1038/s41598-022-08449-w. Sci Rep. 2022. PMID: 35292755 Free PMC article.

6

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study.

Lee SH, Lin YC, Chiu LC, Ju JS, Tung PH, Huang AC, Li SH, Fang YF, Chen CH, Kuo SC, Wang CC, Yang CT, Hsu PC. Lee SH, et al. Among authors: ju js. Ther Adv Med Oncol. 2022 Jul 23;14:17588359221113278. doi: 10.1177/17588359221113278. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35898964 Free PMC article.

7

Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation.

Kuo CS, Chiu TH, Tung PH, Huang CH, Ju JS, Huang AC, Wang CC, Ko HW, Hsu PC, Fang YF, Guo YK, Yang CT. Kuo CS, et al. Among authors: ju js. Cancers (Basel). 2022 Jan 9;14(2):316. doi: 10.3390/cancers14020316. Cancers (Basel). 2022. PMID: 35053480 Free PMC article.

8

Feasibility and Safety of Transbronchial Lung Cryobiopsy for Diagnosis of Acute Respiratory Failure with Mechanical Ventilation in Intensive Care Unit.

Chang CH, Ju JS, Li SH, Wang SC, Wang CW, Lee CS, Chung FT, Hu HC, Lin SM, Huang CC. Chang CH, et al. Among authors: ju js. Diagnostics (Basel). 2022 Nov 23;12(12):2917. doi: 10.3390/diagnostics12122917. Diagnostics (Basel). 2022. PMID: 36552923 Free PMC article.

9

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors.

Hsu PC, Huang CY, Lin YC, Lee SH, Chiu LC, Wu CE, Kuo SC, Ju JS, Huang AC, Ko HW, Wang CC, Yang CT. Hsu PC, et al. Among authors: ju js. Front Oncol. 2023 Oct 3;13:1249106. doi: 10.3389/fonc.2023.1249106. eCollection 2023. Front Oncol. 2023. PMID: 37854677 Free PMC article.

10

Influence of chronic obstructive pulmonary disease on long-term hospitalization and mortality in patients with heart failure with reduced ejection fraction.

Lin CH, Yeh JK, Lin TY, Lo YL, Chang BJ, Ju JS, Chiu TH, Tung PH, Huang YJ, Lin SM. Lin CH, et al. Among authors: ju js. BMC Pulm Med. 2023 Feb 17;23(1):67. doi: 10.1186/s12890-023-02357-z. BMC Pulm Med. 2023. PMID: 36805703 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

14 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year